2023-Mol2Med™ First-Time-Right Approach Webinar Series

In this series, we will discuss how it is possible to accelerate from Candidate Selection to Phase I FIH cost effectively, within 12 months, and with visibility into future clinical trials. A recent survey of 150 biopharmaceutical development scientists concludes:

• Formulation issues have led to project failure and significant delays for about 60% of responding companies.

• Of those projects, a delay of more than 12 months was reported by 52%

• 10% experienced complete failure

This study's findings highlight the importamce of first-time-right development to avoid costly delays.